Publications by authors named "Michael Trautmann"

Claim this Profile
E
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch

BMJ Open Diabetes Res Care· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli

BMJ Open Diabetes Res Care· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch

Diabetes Obes Metab· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Stefano Del Prato, Jahoon Kang, Michael E Trautmann, John Stewart, Christopher H Sorli

Diabetes Obes Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
Richard E Pratley, Jahoon Kang, Michael E Trautmann, Marcus Hompesch, OakPil Han

Diabetes Obes Metab· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch

Diabetes Care· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
Bruno Guerci, Michael E Trautmann, Tim Lin, Elise Hardy, Sunder Raj D Mudaliar

Diabetes Obes Metab· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
Michael E Trautmann, Luc Van Gaal, Jenny Han, Elise Hardy

J Diabetes Complications· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
Michael E Trautmann, Jenny Han, James Ruggles

Clin Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Carol H Wysham, Leigh A MacConell, David G Maggs, Ming Zhou, Peter S Griffin, Michael E Trautmann

Mayo Clin Proc· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Michaela Diamant, Luc Van Gaal, Bruno Guerci, Stephen Stranks, Jenny Han, Michael E Trautmann

Lancet Diabetes Endocrinol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of pancreatic β-cell function: review of methods and clinical applications.
Eugenio Cersosimo, Carolina Solis-Herrera, Michael E Trautmann, Jaret Malloy, Curtis L Triplitt

Curr Diabetes Rev· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
David G Parkes, Kenneth F Mace, Michael E Trautmann

Expert Opin Drug Discov· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Jutta Keller, Michael E Trautmann, Harry Haber, Lai San Tham, Tamsin Hunt

Regul Pept· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Paul Norwood, Joanne F Liutkus, Harry Haber, Ella Pintilei, Marilyn K Boardman, Michael E Trautmann

Clin Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-2-pyridinylmethyl-N'-arylmethyl-diaminomaleonitriles: new highly selective chromogenic chemodosimeters for copper(II).
Thomas Schwarze, Alexandra Kelling, Holger Müller, Michael Trautmann, Tillmann Klamroth

Chemistry· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Baptist Gallwitz, Juan Guzman, Francesco Dotta, Bruno Guerci, Rafael Simó, Michael Trautmann

Lancet· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Michaela Diamant, Luc Van Gaal, Stephen Stranks, Bruno Guerci, Leigh MacConell, Michael Trautmann

Diabetes Care· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Mary Beth DeYoung, Leigh MacConell, Viren Sarin, Michael Trautmann, Paul Herbert

Diabetes Technol Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Michael Trautmann

J Clin Endocrinol Metab· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
Kristin Taylor, Kate Gurney, Jenny Han, Richard Pencek, Brandon Walsh, Michael Trautmann

BMC Endocr Disord· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
John B Buse, Daniel J Drucker, Kristin L Taylor, Terri Kim, Brandon Walsh, Michael Trautmann

Diabetes Care· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
Julio Rosenstock, Leslie J Klaff, Sherwyn Schwartz, Justin Northrup, John H Holcombe, Michael Trautmann

Diabetes Care· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Michaela Diamant, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Michael Trautmann

Lancet· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide once weekly for the treatment of type 2 diabetes.
James Malone, Michael Trautmann, Ken Wilhelm, Kristin Taylor, David M Kendall

Expert Opin Investig Drugs· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis